Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.64 |
| ▸ | MMP9 | P14780 | 5/20 | 0.64 |
| ▸ | MMP8 | P22894 | 5/20 | 0.64 |
| ▸ | MMP13 | P45452 | 5/20 | 0.64 |
| ▸ | VHL | P40337 | 8/20 | 0.48 |
| ▸ | ELOC | Q15369 | 1/20 | 0.41 |
| ▸ | ELOB | Q15370 | 1/20 | 0.41 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1105562 | 1.00 | MMP2 (0.64) | MMP2MMP9MMP8MMP13VHL | |
| SCHEMBL13654267 | 0.85 | MMP2 (0.49) | MMP2MMP9MMP8MMP13VHL | |
| SCHEMBL402605 | 0.85 | MMP2 (0.49) | MMP2MMP9MMP8MMP13VHL | |
| SCHEMBL403669 | 0.77 | CCNC (0.44) | MMP2MMP9MMP8MMP13SLC6A7 | |
| SCHEMBL2692903 | 0.76 | MMP13 (0.43) | MMP2MMP9MMP8MMP13SLC6A7 | |
| SCHEMBL202818 | 0.76 | MMP13 (0.43) | MMP2MMP9MMP8MMP13SLC6A7 | |
| SCHEMBL2693934 | 0.73 | SLC6A7 (0.41) | MMP2MMP9MMP8MMP13SLC6A7 | |
| SCHEMBL13654541 | 0.73 | RXRA (0.39) | MMP2MMP9MMP8MMP13SLC6A7 | |
| SCHEMBL15125820 | 0.72 | VHL (0.56) | MMP2MMP9MMP8MMP13VHL | |
| SCHEMBL8343803 | 0.72 | KMT2A (0.53) | MMP2VHLMEN1KMT2APIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8088804-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8084615-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2011-12-27 | — | — | US | disclosed |
| US-7989660-B2 | BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110172174-A1 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2011-07-14 | — | — | US | disclosed |
| EP-2338878-A2 | N-hydroxyamide derivatives possessing antibacterial activity | Vicuron Pharmaceuticals, Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20100324025-A1 | Antibacterial Agents | UNIVERSITY OF WASHINGTON (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. | 2010-01-28 | — | — | US | disclosed |
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | UNIVERSITY OF WASHINGTON (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
| US-20060154988-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244197-A1 | Antibacterial agents | MRPL21, SI, PGLS | MMP2 450/4885MMP9 1472/4885MMP8 108/4885 |
| US-20090247506-A1 | Antibacterial agents | MRPL21, SI, PGLS | MMP2 450/4885MMP9 1472/4885MMP8 108/4885 |
| US-20110172174-A1 | Antibacterial agents | MRPL21, SI, PGLS | MMP2 450/4885MMP9 1472/4885MMP8 108/4885 |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | MMP2 450/4885MMP9 1472/4885MMP8 108/4885 |
| US-20060154988-A1 | Antibacterial agents | MRPL21, SI, PGLS | MMP2 450/4885MMP9 1472/4885MMP8 108/4885 |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | NAAA, HDHD5, HACL2 | MMP2 1855/4885MMP9 1667/4885MMP8 162/4885 |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | MMP2 450/4885MMP9 1472/4885MMP8 108/4885 |
| US-20100324025-A1 | Antibacterial Agents | MRPL21, SI, PGLS | MMP2 450/4885MMP9 1472/4885MMP8 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.